GlycanAge

GlycanAge develops glycan biomarker diagnostics to measure biological ageing and chronic inflammation.

London, UK—Founded 2016—Website

$12.0MTotal raised

London-based biotechnology startup developing glycan biomarker diagnostics to measure biological ageing and track chronic inflammation.

Founders

Gordan Lauc

CSO

Gordan serves as chief scientific officer of GlycanAge and chief executive of Genos, alongside academic posts at the University of Zagreb and King's College London. He brings extensive biochemical and academic experience to his ventures.

Nikolina Lauc

CEO

Nikolina is the chief executive and co-founder of GlycanAge. She previously co-founded Lime Street and Raggedy.

Investors

18 December 2025
$8.7M
FQ
Fifth Quarter VenturesLead
Guinness Ventures
BV
BrightCap Ventures
South Central Ventures
IC
Impetus Capital
VD
Vesna Deep Tech
LE
Lightfield Equity
LV
LaunchHub Ventures
Kadmos CapitalFollow-on
Seed19 February 2024
£3.3M
L
LAUNCHubLead
Kadmos CapitalLead

Funding history

18 December 2025

$8.7M

GlycanAge raises $8.7m led by Fifth Quarter Ventures to expand hospital diagnostics

The funding round will support the development of hospital-ready diagnostic products and broaden clinical access to glycan testing.

Seed19 February 2024

£3.3M

GlycanAge secures £3.3m in seed funding led by LAUNCHub Ventures and Kadmos Capital to expand into diagnostics.

The financing round was led by LAUNCHub Ventures and Kadmos Capital to fund the company's shift towards the diagnostics market.